MicroRNAs (miRNAs) are small non-coding RNAs, 18-25 nucleotides long and have an important role in post-transcriptional regulation of gene. Several aspects of cellular activities such as cell growth, proliferation and differentiation are regulated by miRNAs. In many cancers and malignancies, up-or downregulation of different miRNAs has been reported. In human hepatocellular carcinoma (HCC), upregulation of miR-21 has been reported in human in vitro studies. Here, we made an assessment of the effect of miR-21 degradation on viability and apoptosis of HCC cell line (HepG2) using locked nucleic acid (LNA). At different time points (24, 48, 72 h) after LNA-anti-miR-21 transfection, 3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide assay and Annexin/ propidium iodide staining were performed. The results show that miR-21 degradation can decrease the viability of cells, mainly by induction of apoptosis and necrosis. These findings suggest that degradation of miR-21 could be used as a novel approach in treatment of HCC.
INTRODUCTION
MicroRNAs (miRNAs) have been recognized as post-transcriptional regulators of gene expression involved in many cellular, biological and pathological activities. 1 Initially discovered in 1993 in Caenorhabditis elegans, miRNAs were later shown to play definitive roles in regulation of gene expression. They are composed of short RNA chains, 18-25 nucleotides long. 2 MiRNAs are involved in different biological processes, including cell cycle, differentiation, growth and development, metabolism, aging and apoptosis. 3 Dysregulation of miRNAs including both down-and upregulation of their biogenesis, mimics the phenomenon related to the oncogenes and tumor-suppressor genes, depending on the target mRNA regulated by particular species of miRNAs. [4] [5] [6] In addition, many reports have pointed out their essential function in a wide range of diseases, including heart and cardiovascular diseases, rheumatologic, infectious, inflammatory, autoimmune, metabolic disorders and cancers. 3, [7] [8] [9] Being one of the most frequently diagnosed cancers worldwide, liver cancer is the second leading cause of cancer-death in men and the sixth leading cause of cancer-related death in women. 10 Human hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and the third cause of cancer-related deaths. 11, 12 HCC, which accounts for 70-85% of the primary liver cancer cases, is rarely detected in its early stage, resulting in a short survival of a few months. 11 About 90% of HCC cases arise from cirrhosis, which can be attributed to a wide range of factors, including chronic viral hepatitis B or C infections, alcohol abuse, nonalcoholic steatohepatitis, autoimmune hepatitis, primary biliary cirrhosis and carcinogen exposure. 13, 14 Significant progress on unraveling the molecular mechanisms of HCC has been recently achieved, paving the way to the early detection and treatment of HCC. 15 Tumor-suppressor Pdcd4 inhibits transformation and invasion; it is downregulated in cancers. 16 Pdcd4 is negatively regulated by miR-21. 17 MiR-21 located on chromosome 17q23-2 (http://www. mirbase.org). In mammals, miR-21 has been shown to exhibit anti-apoptotic activity in human glioblastoma cells, and miR-21 ablation triggered activation of caspases and led to increased apoptotic cell death. 18 miR-21 induces invasion/intravasation/ metastasis. 19 Therefore, we focused our studies on miR-21.
Many methods have been tested for degradation of miRNAs. 4, [20] [21] [22] Locked nucleic acid (LNA) is a new lineage of modified oligonucleotide that has a 2'-O 4'-C Methylene bridge in its structure leading to consistently high temperature and resistance to enzymatic degradation. [23] [24] [25] The effect and safety of LNA-anti-miRs for degradation of miRNAs have been shown in several studies, suggesting them as suitable candidates for therapeutic applications. 23, 26 In this study, we have used LNA-anti-miR for degradation of miR-21 in HCC. Cell proliferation, apoptosis and necrosis were assessed. The results of this study may pave the way toward new therapies for HCC.
MATERIALS AND METHODS

Cell culture
HepG2 cell line (hepatocarcinoma) was purchased from National Cell Bank of Iran (Pasteur Institute, Tehran, Iran). The cell culture was kept in Roswell Park Memorial Institute (RPMI) 1640 (Gibco, Paisley, UK) supplemented with fetal bovine serum (FBS; Gibco) 15% (v/v), 100 U ml − 1 of penicillin and 100μg ml − 1 of streptomycin (Sigma-Aldrich, St Louis, MO, USA) in an airsaturated and humid atmosphere consisting of 5% CO 2 in 75-cm 2 culture flasks (Nunc, Roskilde, Denmark) at 37°C. Cells were passaged twice weekly to maintain exponential growth phase.
Cell transfection
Nucleotide sequences of miR-21 were obtained from http://www.mirbase. org as 5'-UAGCUUAUCAGACUGAUGUUGA-3' (accession number MIMAT0000076). miRCURY LNA miRNA inhibitor for hsa-miR-21 and miRNA inhibitor for negative control (scrambled) oligonucleotides were purchased 1 from Exiqon (Copenhagen, Denmark). Both oligonucleotides of LNA and scrambled were labeled at the 5' end with fluorescent dye, 6-carboxyfluorescein.
HepG2 cell transfection was performed by using X-tremeGENE siRNA Transfection Reagent (Roche, Mannheim, Germany) according to the manufacturer's instructions. Summary, 5 × 10 5 cells in exponential growth phase were cultured in six-well culture plates (Nunc) containing 1.8 ml RPMI-1640 per wheel without antibiotic and FBS. Forty picomoles miRCURY LNA miRNA Inhibitor was mixed with 4 μl X-tremeGENE siRNA Transfection Reagent in 200 μl Opti-MEM I Medium (Gibco) and incubated for 17 min at room temperature. The complex was then added to the cells and swirled discreet to ensure even distribution over the entire plate surface. After 8 h of incubation, FBS and antibiotics were added and the cells were incubated for the 24, 48 and 72 h. Untreated cells and cells transfected with scrambled LNA were cultured parallel to LNA-anti-miR-transfected cells. Assessment of transfection was made by Flow cytometry and fluorescent microscopy. LNA was conjugated to 6-carboxyfluorescein and HepG2 cells that were transfected with LNA and were seen by fluorescence microscope and were analyzed by FACSCalibur Flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA).
Reverse transcriptase (RT) miRNA real-time PCR
RT miRNA real-time PCR was performed to determine the performance of miR-21 degradation by LNA-anti-miR. In short, total cellular RNA was extracted after 24, 48 and 72 h post transfection with miRCURY RNA Isolation Kit (Exiqon) and cDNA was synthesized by Universal cDNA Synthesis Kit (Exiqon). Real-time PCR was performed by using SYBR Green master mix Kit (Exiqon) and specific miR-21 primers were obtained from Exiqon. ABI_StepOnePlus (Applied Biosystems, Foster City, CA, USA) instrument was used for real-time PCR test and ΔΔCt method was used for data calculation.
Cells viability assay
The survival of cells was assessed by MTT (3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide, (Sigma-Aldrich)) assay, which is based on the decrease of MTT by the mitochondrial dehydrogenase of intact cells to a purple formazan product. The shift is directly related to the number of living cells. MTT assay was performed at intervals of 24, 48 and 72 h post transfection. Two hundred microliters of MTT at the concentration of 50 mg ml − 1 were added to 5 × 10 5 HepG2 cells suspended in 2 ml RPMI-1640 medium and incubated for 2 h at 37°C in the dark. Then, two hundred microliters of dimethyl sulfoxide (Sigma-Aldrich) were added to each well and was shaken until resolution of crystals. Blank sample was prepared using exactly the same manner with exception of Cell Corporation. Absorbance was measured by using a spectrophotometer (PG Instrument T80, PG Instrument, Leicestershire, England) at 570 nm. Reading was transformed to the percentage of the controls.
Apoptosis and necrosis assay
Annexin-V-FLUOS Staining Kit (Roche) was used for detection of apoptosis and necrosis in HepG2 cells. Annexin-V was used to discover phosphatidylserine on apoptotic cells. To discriminate necrotic cells propidium iodide (PI) staining was performed (untreated cells were used for control). The manner was performed at 24, 48 and 72 h after transfection according to the manufacturer's instruction and the cells were assessed by FACSCalibur Flow cytometer (BD) with 488 nm excitation, 515 nm bandpass filter for fluorescein-conjugated Annexin-V detection and a filter 4600 nm for PI detection.
Statistical analysis
All experiments were performed in triplicate. The results were computed by SPSS Version 22 (IBM, NY, USA) software. Two-way analysis of variance test was used to assess differences between groups. Data are presented as mean ± s.d. Statistical significance was defined as Po0.05.
RESULTS
miRCURY LNA miRNA Inhibitor strongly inhibit miR-21 For degradation of miR-21, miRCURY LNA miRNA inhibitor was transfected to HepG2 cells with X-tremeGENE siRNA Transfection Reagent. Based on primary optimization experiments, transfection was performed with 40 pM of LNA-anti-miR and 4 μl Expression of miR-21 was evaluated by reverse transcriptase miRNA real-time PCR in HepG2 cells transfected with miRCURY LNA miRNA inhibitor (LNA-anti-miR group), transfected with miRNA inhibitor scrambled oligonucleotides (scrambled LNA group) or untreated HepG2 cells (untreated groups) at 24, 48 and 72 h after transfection. Although the miR-21 expression was a little bit lower in scrambled LNA-transfected cells compared with untreated cells, the differences were not biologically significant and the miR-21 level was in the same order as of these two groups. However, in all three time points, the expression of miR-21 was considerably lower in LNA-anti-miR group compared with control groups (P o 0.001; Figure 2 ).
Degradation of miR-21 decreased viable HepG2 cells
To assess the effect of miR-21 degradation on cell viability, MTT assay was performed 24, 48 and 72 h after transfection. Cell viability was lower in the scrambled LNA group compared with untreated cells at 48 and 72 h after transfection (P o 0.02). Cell viability of HepG2 cells was considerably decreased after LNA-Anti-miR transfection. The effect of LNA-Anti-miR transfection on cell viability gradually increased over time as the viability of LNA-Anti-miR-transfected cell was less than 50% of untreated cells at 72 h after transfection (Figure 3) . The difference of cell viability between LNA-Anti-miR and both control groups was statistically considerable (P o 0.02) in all three time points.
Degradation of miR-21 increased apoptosis and necrosis in HepG2 cells
To assess the effect of miR-21 degradation on apoptosis and necrosis, the cells were stained with Annexine-V and PI at 24, 48 and 72 h post transfection. Apoptotic cells were almost undetectable in untreated cells. However, the ratio of these cells minimally increased 48 and 72 h after scrambled LNA transfection compared with untreated cells (P o 0.001 for both time points). miR-21 degradation was associated with dramatic increment of apoptosis as the ratio of apoptotic cells in LNA-anti-miR group was higher than the other group in the three time points (P o 0.001; Figure 4 ).
In line with the data of apoptosis assay, necrosis in untreated cells was undetectable but the ratio of necrotic cells minimally increased 48 and 72 h after scrambled LNA transfection compared with untreated cells (P o 0.001 for both time points). The ratio of necrotic cells in LNA-anti-miR group was higher than the other groups in the three time points, which shows degradation of miR-21 is associated with increment of necrosis in HepG2 cells (P o 0.001; Figure 5 ).
DISCUSSION
HCC is one of the most common cancers worldwide and the third cause of cancer-related deaths. 27 Poor understanding of the mechanisms underlying the pathogenesis of HCC makes it difficult to be diagnosed and treated at an early stage. 10 MiRNAs are known to function as either tumor suppressors or oncogenes (oncomiRs). 28 Modification of the function of these miRNAs can present new therapeutic options. 20 In this study, we have used LNA-anti-miR to degrade miR-21 in HepG2 cell line. Real-time PCR data confirmed that this miRNA was almost exactly downregulated after LNA-anti-miR transfection. MTT assay showed that the viability of degradation of miR-21 is associated with decrease of cell viability. These data were confirmed further by apoptosis/necrosis assay, showing that LNA-anti-miR-21 transfection significantly increases apoptosis/necrosis. Although, due to transfection reagent toxicity, cell viability was minimally decreased after scrambled LNA transfection, we suspect that the effect of LNA-anti-miR-21 transfection on cell viability was much higher than this basic level. In addition, we realize that our Annexin-V/PI staining method cannot discriminate between late apoptosis and necrosis. However, our data indicate that degradation of miR-21 can decrease the viability of HepG2 cells and this is at least partially due to induction of apoptosis.
Tumor-suppressor Pdcd4 is negatively regulated by miR-21 at the post-transcriptional level, via a specific target site (nt228-249) within the 3'-UTR. 17, 29 This is interesting since miR-21 has been shown to act as an anti-apoptotic factor in glioblastoma cells. 30 Previous studies reported that miR-21 can inhibit apoptosis by regulating Bcl-2 in a breast cancer mouse model and that gemcitabine-induced apoptosis is specifically inhibited by miR-21 via phosphatase and tensin homolog and the 17 miR-21 is one of the most prominent miRNAs implicated in the genesis and progression of human cancer, not only has it been implicated in the promotion of tumor growth, proliferation, antiapoptosis and response to gemcitabine-based chemotherapy, but also diverse studies have shown that miR-21 is being overexpressed in different tumor types. 16, 19, 29 Researchers were investigated 157 miRNAs in five human breast cancer and matched normal tissues, and found an overexpression of miR-21 in tumors, confirming an earlier study on human breast cancer samples found an overexpression of miR-21 in glioblastoma tissues, and reported that malignant cholangiocytes overexpress miR-21, in addition to other miRNAs such as let7a-1/miR-16-1. 31, 32 One of the largest and most systematic studies on miRNA expression determined several patterns of differentially expressed miRNAs, some of which again included miR-21, in diverse human tumors, taking into consideration potential biases such as tumor differentiation. 31, 33 There are a lot of studies on oncomiRs as an approach in cancer treatment and efforts have been made for treatment of cancer using miRNA inhibitors. 1, 4, [34] [35] [36] Many studies are in the primary phase and some are in other phases. 37 One of the Anti-miRs is LNA that was used to inhibit oncomiRs. 23 In this study, it was determined that degradation of miR-21 with LNA-anti-miR could prevent miR-21 and human hepatocellular carcinoma Z Najafi et al proliferation of HepG2 cells and seemed that miR-21 is an oncomiR in HCC. In treatment of cancer, the destruction of cells with uncontrolled proliferation seems to be an aim. Therefore, in the treatment of HCC, LNA-anti-miR may be used to degrade miR-21. Some efforts were made to treat cancer by Anti-oncomiRs (oncomiR-inhibitors) accompanied with other drugs such as chemotherapy agents. [38] [39] [40] This suggests that Anti-miR-21 accompanied with other anticancer drug can be used in the treatment of HCC. On the other hand, there have been some cases that oncomiR degradation acts to sensitize the cells to chemotherapy agents, making these combination therapies more effective than when any one of the strategies is used alone. 38 For example, miR-122 mimetic alone or in combination with anticancer drugs can be a promising therapeutic regimen against liver cancer. 41 The results presented here suggest that Anti miR-21 can be used with or without anticancer drugs in the treatment of HCC that is resistant to treatment.
MiRNAs therapy will move to the stage of clinical trials and along with Anti-oncomiR will be used to treat cancer. Our data suggest that the degradation of miR-21 with LNA-anti-miR can be potentially used for treatment of HCC. It can be used alone or in combination with prevalent therapies to decrease the existing limitations in the treatment of this disorder. Further, in vivo studies are definitely essential to assess the feasibility of this strategy. Representative cytofluorometric graphs are shown in (a). The ratio of necrotic cells in locked nucleic acid (LNA)-anti-miR group was higher than the other groups in the three time points. The data shown in the graph are mean ± s.d. of three independent experiments. P o0.001 (b). miR-21 and human hepatocellular carcinoma Z Najafi et al However, effective in vivo delivery of anti-miR oligonucleotides remains an impediment to be tackled before we can move to clinical trials.
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